The price of Bluebird bio Inc (NASDAQ:BLUE) shares last traded on Wall Street fell -3.64% to $0.36.
BLUE stock price is now -25.98% away from the 50-day moving average and -60.33% away from the 200-day moving average. The market capitalization of the company currently stands at $70.31M.
, while ‘Morgan Stanley’ rates the stock as ‘Equal-Weight’
In other news, Klima Thomas J, insider sold 1,006 shares of the company’s stock on Sep 30 ’24. The stock was sold for $529 at an average price of $0.53. Upon completion of the transaction, the insider now directly owns 170,000 shares in the company, valued at $61200.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 30 ’24, President and CEO Obenshain Andrew sold 34,780 shares of the business’s stock. A total of $18,270 was realized by selling the stock at an average price of $0.53. This leaves the insider owning 375,218 shares of the company worth $0.14 million. A total of 0.89% of the company’s stock is owned by insiders.
During the past 12 months, Bluebird bio Inc has had a low of $0.34 and a high of $5.53. As of last week, the company has a debt-to-equity ratio of 7.37, a current ratio of 0.68, and a quick ratio of 0.57. The fifty day moving average price for BLUE is $0.4942 and a two-hundred day moving average price translates $0.9174 for the stock.
The latest earnings results from Bluebird bio Inc (NASDAQ: BLUE) was released for 2024-06-30. The net profit margin was -553.28% and return on equity was -177.63% for BLUE. The company reported revenue of $16.1 million for the quarter, compared to $6.89 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 133.69 percent.
